At a glance
ClinicalIndex Comparison RecordN/ACompleted· 194 enrolled
Drug / intervention
Atrial fibrillation ablationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation (CASTLE-HTx)
Heart and Diabetes Center North-Rhine Westfalia·interventional·Posted Dec 2, 2020·Updated May 17, 2023
In Brief
A clinical study evaluating Atrial fibrillation ablation for Heart Failure and Atrial Fibrillation. Completed, enrolled 194 participants across 1 site.
Detailed Summary
CASTLE-HTx will determine if AF ablation has beneficial effects on mortality in patients with end stage HF who are eligible for HTx
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Atrial Fibrillation
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionDec 2022
Study CompletionMay 2023
TodayJul 2026
First PostedDec 2, 2020
Enrollment StartDec 1, 2020
Primary CompletionDec 31, 2022
Study CompletionMay 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.6 years ago
Interventions
Atrial fibrillation ablationprocedure
Catheter ablation